What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg ‐negative anti‐ HBc ‐positive patients? Meta‐analysis and decision curve analysis
Liver International · 2024
DOI: 10.1111/liv.16064 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Liver International, 2024. Verfasst von Ciro Celsa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Promotion, Section of Gastroenterology and Hepatology, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B Core Antigens, Hepatitis B virus, Hepatitis B, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union - NextGenerationEU through the Italian Ministry of University and Research, European Union-FESR or FSE.
Abstract (Originalsprache)
Background and Aims Patients with overt or occult hepatitis B virus (HBV) infection receiving immunosuppressive treatments have a wide risk of HBV reactivation (HBVr). We performed meta‐analysis with decision curve analyses (DCA) to estimate the risk of HBVr in HBsAg‐negative anti‐HBc‐positive patients naïve to nucleos(t)ide analogues (NAs) receiving immunosuppressive treatments. Approach and Results Studies were identified through literature search until October 2022. Pooled estimates were obtained using random‐effects model. Subgroup analyses were performed according to underlying disease and immunosuppressive treatments. DCA was used to identify the threshold probability associated with the net benefit of antiviral prophylaxis in HBsAg‐negative anti‐HBc‐positive patients. We selected 68 studies (40 retrospective and 28 prospective), including 8034 patients with HBsAg negative anti‐HBc positive. HBVr was 4% (95% CI 3%–6%) in HBsAg‐negative anti‐HBc‐positive patients, with a significantly high heterogeneity ( I 2 69%; p < .01). The number‐needed‐to‐treat (NNT) by DCA ranged from 8 to 24 for chemotherapy plus rituximab, from 12 to 24 for targeted therapies in cancer patients and from 13 to 39 for immune‐mediated diseases. Net benefit was small for monoclonal antibodies. Conclusions Our DCA in HBsAg‐negative anti‐HBc‐positive patients provided evidence that NA prophylaxis is strongly recommended in patients treated with chemotherapy combined with rituximab and could be appropriate in patients with cancer treated with targeted therapies and in patients with immune‐mediated diseases. Finally, in patients with cancer treated with monoclonal antibodies or with chemotherapy without rituximab, the net benefit is even lower.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Promotion, Section of Gastroenterology and Hepatology, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.
- Department of Surgery & Cancer, Imperial College London, London, UK.
- Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Palermo, Italy.
- Department of Diagnostic and Therapeutic Services, The Mediterranean Institute for Transplantation and Highly Specialized Therapies (ISMETT), Palermo, Italy.
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.
- Department of Economic, Business and Statistical Sciences, University of Palermo, Palermo, Italy.
ORCID-Profile: Ciro Celsa, Giacomo E M Rizzo, Salvatore Petta, Giuseppe Cabibbo, Vincenza Calvaruso, Calogero Cammà, Vito Di Marco
Förderung
- European Union - NextGenerationEU through the Italian Ministry of University and Research
- European Union-FESR or FSE
Zitieren
APA
Celsa, C., Rizzo, G. E. M., Di Maria, G., Enea, M., Vaccaro, M., Rancatore, G., Graceffa, P., Falco, G., Petta, S., Cabibbo, G., Calvaruso, V., Craxì, A., Cammà, C., & Di Marco, V. (2024). What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg ‐negative anti‐ HBc ‐positive patients? Meta‐analysis and decision curve analysis. Liver International. https://doi.org/10.1111/liv.16064
Vancouver
Celsa C, Rizzo GEM, Di Maria G, Enea M, Vaccaro M, Rancatore G, et al. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg ‐negative anti‐ HBc ‐positive patients? Meta‐analysis and decision curve analysis. Liver International. 2024. doi:10.1111/liv.16064
BibTeX
@article{Celsa2024,
author = {Celsa, Ciro and Rizzo, Giacomo E M and Di Maria, Gabriele and Enea, Marco and Vaccaro, Marco and Rancatore, Gabriele and Graceffa, Pietro and Falco, Giuseppe and Petta, Salvatore and Cabibbo, Giuseppe and Calvaruso, Vincenza and Craxì, Antonio and Cammà, Calogero and Di Marco, Vito},
title = {What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg ‐negative anti‐ HBc ‐positive patients? Meta‐analysis and decision curve analysis},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.16064}
}
EUVIMED